Central Effects of Endogenous GLP-1 and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

Trial Profile

Central Effects of Endogenous GLP-1 and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Liraglutide (Primary) ; Glucagon-like peptide-1; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms LIBRA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 09 May 2012 Actual initiation date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top